共 23 条
[1]
Parkin D.M.(2005)Global cancer statistics, 2002 CA Cancer J Clin 55 74-108
[2]
Bray F.(2008)Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 217-33
[3]
Ferlay J.(2004)The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 319 1-11
[4]
Arpino G.(2005)Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 7350-60
[5]
Wiechmann L.(2000)Molecular portraits of human breast tumours Nature 406 747-52
[6]
Osborne C.K.(2009)How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer J Clin Oncol 27 5492-4
[7]
Roskoski R.(2009)Lapatinib: a review of its use in the treatment of HER2-over-expressing, trastuzumab-refractory, advanced or metastatic breast cancer Drugs 69 2125-48
[8]
Brenton J.D.(2010)Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer Drugs 70 1411-22
[9]
Carey L.A.(2010)Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer Oncologist 15 122-9
[10]
Ahmed A.A.(2009)Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 5538-46